Biogen Idec Company Description
When it comes to developing new and better biotech drugs, Biogen Idec believes two heads are better than one. The biotech giant, formed from the merger of IDEC Pharmaceuticals and Biogen, is focused on developing treatments in the areas of oncology, immunology, and neurology. Its product roster includes best-selling Avonex, the most popular drug for the treatment of relapsing multiple sclerosis; Rituxan, a monoclonal antibody developed with Genentech that treats B-cell non-Hodgkin's lymphoma (NHL); multiple sclerosis drug Tysabri; and Fumaderm, a psoriasis drug marketed in Germany.
View the Comprehensive Company Description for Biogen Idec
The Company Description provides a historical perspective of Biogen Idec's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Biogen Idec's evolution in the marketplace.
